CD19 and leukemia: This approach has been particularly successful in the management of leukemias with the clonal expansion of neoplastic cells that bear well-defined differentiation antigens, such as CD19 on chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL), which are eradicated upon CD19-specific CAR-T cell targeting.